Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Allergan Plc (AGN) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 81,227,328
  • Shares Outstanding, K 395,950
  • Annual Sales, $ 15,071 M
  • Annual Income, $ 3,915 M
  • 36-Month Beta 1.02
  • Price/Sales 6.65
  • Price/Book 1.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
191.00 +12.22%
on 12/21/16
223.29 -4.01%
on 01/10/17
+23.01 (+12.03%)
since 12/20/16
3-Month
184.50 +16.17%
on 11/23/16
232.41 -7.78%
on 10/21/16
-18.74 (-8.04%)
since 10/20/16
52-Week
184.50 +16.17%
on 11/23/16
301.98 -29.02%
on 01/22/16
-78.60 (-26.83%)
since 01/20/16

Most Recent Stories

More News
Novartis (NVS) Q4 Earnings: Stock Likely to Disappoint?

Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report fourth-quarter and full year 2016 results on Jan 25.

Allergan (AGN) Rhofade Cream for Rosacea Approved in U.S.

Allergan plc (AGN) announced that the FDA has approved Rhofade (oxymetazoline hydrochloride) cream for topical treatment of persistent facial erythema (redness) associated with rosacea in adults.

North America Facial Injectable Market to be Worth US$5.8 Billion by 2024: Focus on Physical Appearance Encourages Users to Undergo Minimally Invasive Surgeries, Notes TMR

The North America Facial Injectables Market is quite monopolistic in nature with one player dominating the overall market dynamics. As of 2016, Allergan Plc., held a share 62.0% in the regional market....

Should Value Investors Choose Allergan (AGN)?

Allergan (AGN) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

Apricus (APRI) Stock Gains on Vitaros' Approval in Mexico

Apricus (APRI) announced that Vitaros was approved in Mexico for the treatment of patients with erectile dysfunction.

Biogen (BIIB) Q4 Earnings: What's in Store for the Stock?

Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will be reporting fourth-quarter 2016 and full-year earnings on Jan 26.

Vertex Pharma (VRTX) Q4 Earnings: Stock Likely to Beat?

We expect biotech company Vertex Pharmaceuticals, Inc. (VRTX) to beat expectations when it reports fourth-quarter 2016 and full-year earnings results on Jan 25, after the market closes.

Allergan's Uterine Fibroids Candidate Positive in Phase III

Allergan Plc (AGN) and European specialty pharma company Gedeon Richter reported encouraging results from a phase III study on their pipeline candidate, ulipristal acetate, in women with abnormal bleeding...

Allergan Paying $15 Million Penalty for Disclosure Failures During Merger Talks

Allergan and Gedeon Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids

Allergan Plc (NYSE: AGN) and Gedeon Richter Plc. today announced positive results from Venus II, the second of two pivotal phase III clinical trials evaluating the efficacy and safety of ulipristal acetate...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan...

See More

Support & Resistance

2nd Resistance Point 217.45
1st Resistance Point 215.90
Last Price 214.34
1st Support Level 212.96
2nd Support Level 211.57

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.